The core market in which Vectura operates is in inhaled airways disease. Prior to the merger with Skyepharma, Vectura had two legacy revenue-contributing non-inhaled assets partnered with Baxter (ADVATE® and Adept®). The Group’s ADVATE® patent expired at the end of January 2016; however, owing to higher than anticipated production of ADVATE® inventory by Baxter prior to this expiry, Vectura has continued to receive royalties from sales of this product totalling £8.2m for the period under review (2015/16: £12.7m). Adept® continues to make a minor contribution to revenue. Skyepharma also had twelve revenue-contributing oral and non-inhaled products including the topical product Solaraze®, partnered in the US with Sandoz and Almirall in Europe/ROW, and Pacira’s injectable, EXPAREL®. 

Marketed products

Solaraze®

Solaraze®

(diclofenac sodium 3%)

Solaraze was developed by Vectura(1) using its proprietary technologies.

  • Primary indicationactinic keratoses
  • PartnersSandoz (US) and Almirall (EU)
  • Descriptiona nonsteroidal anti-inflammatory drug (NSAID) treating actinic keratosis, a precancerous skin growth usually caused by sun exposure.

EXPAREL® (US)

EXPAREL® (US)

(bupivacaine liposome injectable suspension)

Exparel, was initially developed by Vectura(1) and the development was completed by Pacira Pharmaceuticals following the sale of Skyepharma’s injectable business.

  • Primary indicationadmininistration into the surgical site to produce post-surgical analgesia
  • PartnerPacira Pharmaceuticals
  • DescriptionInjectable product for single-dose administration into the surgical site to produce post-surgical analgesia.

Adept® (Global) - Icodextrin

Adept® (Global) - Icodextrin

  • Primary indication: Prevention of surgical adhesions
  • Partner: Baxter
  • Description: Adept® is a 4% icodextrin solution used during surgery to reduce post-surgical adhesions, a frequent and major complication after gynaecological and other abdominal surgery, where abnormal scarring causes the surfaces of internal structures to stick together.

    Whilst not necessarily dangerous in themselves, they can lead to future complications, often years later or if further abdominal surgery is required. It has been used in Europe since 2000 and since 2006 in the US

  • History: In December 2005, Vectura signed a licence deal with Baxter for the manufacture and distribution of Adept®

ADVATE® (Global)(2) - Antihaemophilic Factor (Recombinant)

ADVATE® (Global)(2) - Antihaemophilic Factor (Recombinant)

  • Primary indication: Haemophilia A
  • Partner: Baxter
  • DescriptionFor the treatment of haemophilia A and marketed worldwide by Baxter, from which Vectura earns royalties from sales
  • History: In 2000, Vectura granted worldwide rights to Baxter to use its stabilisation patents in its serum-free recombinant Factor VIII, ADVATE®

(1) As legacy Skyepharma part of the business


back to top